Drug interactions with the taxanes

Pharmacotherapy

Volumn 17, Issue 5 II SUPPL., 1997, Pages

  Baker, Sharyn D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; IFOSFAMIDE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CONFERENCE PAPER; DRUG CLEARANCE; HUMAN; LIVER MICROSOME; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG INTERACTIONS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; TAXOIDS;

EID: 0030815493     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991;9:1692-1703.
2. Bookman MA, McGuire WP III, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-1902.
3. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics on the absence and presence of paclitaxel. Clin Cancer Res 1996;2:549-52.
4. Huizing MT, Giuseppe G, vanWarmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 1997;15:317-29.
5. Kearns CM, Belani CP, Erkmen K, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin associated thrombocytopenia [abstr]. Proc Am Soc Clin Oncol 1995;14:170.
6. Kennedy MJ, Zahurak ML, Donehower RC, et al. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 1996;14:783-91.
7. Tolcher AW, Cowan KH, Noone M, et al. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 1996;14:95-102.
8. Holmes FA, Madden T, Newman RA, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996;14:2713-21.
9. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
10. Fisherman JS, Cowan KH, Noone M, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996;14:774-82.
11. Berg SL, Cowan KH, Balis FM, et al. Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994;86:143-5.
12. O'Reilly S, Fleming GF, Baker SD, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 1997;15: 177-86.
13. Pronk LC, Schellens JHM, Planting AST, et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997;15:1071-9.
14. Kalla S, Bourgeois H, Gruia G, et al. Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC): a phase I dose finding study - final results [abstr]. Ann Oncol 1996;7:124.
15. Bourgeois H, Gruia G, Dieras V, et al. Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC): a phase I dose finding study [abstr]. Proc Am Soc Clin Oncol 1996;15:148.
16. Schrijvers D, Pronk L, Schellens J, et al. A phase I and pharmacokinetic study of docetaxel and ifosfamide in patients with advanced solid tumors [abstr]. Ann Oncol 1996;7:125.
17. Watanabe T, Adachi I, Sasaki Y, et al. A phase I/II study of docetaxel (dTx) in combination with 5-fluorouracil (5FU) for advanced or recurrent breast cancer [abstr]. Ann Oncol 1996;7:21.
18. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochrome P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56:58-65.
19. Ma J, Verweij J, Planting AST, et al. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 1996;37:382-4.
20. Sledge GW, Robert N, Sparano JA, et al. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 1995;22:105-8.
21. Madden T, Van NT, Newman RA. Sequence-dependent synergy of paclitaxel and doxorubicin in human breast cancer cell lines. J Exp Ther Oncol In press.
22. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994;54:386-92.
23. Harris JW, Rahman A, Kim BR, Guengreich FP, Collins JM. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
24. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6.
25. Jamis-Dow CA, Kleeker RW, Katki AG, Collins JM. Metabolism of Taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995;36:107-14.
26. 2-receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother Pharmacol 1995;36:227-32.
27. Rhone-Poulenc Rorer. Taxotere (docetaxel) package insert. Collegeville, PA; 1996.
28. Fetell MR, Grossman SA, Fisher J, Erlanger B, Stockel J, Piantadosi S. Pre-irradiation paclitaxel in glioblastoma multiforme (GBM): efficacy, pharmacology, and drug interactions [abstr]. Proc Am Soc Clin Oncol 1996;15:153.
29. Chang S, Schold C, Spence A, et al. Phase I/II study of paclitaxel chemotherapy for recurrent malignant glioma: preliminary report from the North American Brain Tumor Consortium [abstr]. Proc Am Soc Clin Oncol 1996;15:153.
30. Rischin D, Webster LK, Millward MJ, et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 1996;88:1297-1301.